There are difficult, dubious contract negotiations, and then there are contract negotiations where the hardest part is ...

The development of efficient and safe delivery systems is a cornerstone of gene therapy and genome editing. Lipid nanoparticles (LNPs), adeno-associated ...

The New York Rangers could weaponize their #5 overall selection in the 2026 NHL Draft, and land a high-end RFA from the Dallas Stars.

The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best small cap stocks to buy for 10x potential. Taysha Gene Therapies ...

Regeneron's Otarmeni was recently FDA approved for patients with OTOF-related hearing loss based on CHORD trial results.

Viral vectors are key delivery tools for advanced therapies, enabling gene transfer to treat inherited disorders, cancer and other serious diseases. Despite rapid clinical progress, manufacturing ...

Total Revenue: Revenue was $1.3 million for the first quarter of 2026, which was derived from the conduct of preclinical development activities for a second collaboration candidate targeting an ...

Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments ...

VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations ...

Trisk Bio Ltd, a UK-based AAV contract development and manufacturing organisation (CDMO), and NanoMosaic, Inc., a leader in advanced analytical technologies for cell and gene therapy, today announced ...